📊 GOVX Key Takeaways
Is GeoVax Labs, Inc. (GOVX) a Good Investment?
GeoVax Labs is a pre-revenue pharmaceutical company in severe financial distress with zero revenue generation, operating losses of $5.3M, and negative free cash flow of -$3.5M. With only $1.3M in cash and a burn rate exceeding available reserves, the company faces critical liquidity challenges and viability concerns without immediate capital infusion or breakthrough revenue generation.
GeoVax generates minimal revenue and posts extremely negative margins and returns, with operating cash burn far exceeding its cash balance. Despite being debt-free with a decent current ratio, the business appears reliant on external financing and uncertain pipeline progress, leaving fundamentals weak.
GeoVax Labs, Inc. Key Strengths (GOVX)
- Minimal debt burden with Debt/Equity ratio of 0.00x
- $1.3M in cash provides near-term operational runway
- No significant capital expenditure requirements
- Debt-free balance sheet
- Solid current/quick ratio supporting near-term liquidity
- Asset-light with minimal capex requirements
GOVX Stock Risks: GeoVax Labs, Inc. Investment Risks
- Zero revenue with no commercial products generating sales
- Operating cash burn of $3.5M annually against $1.3M cash reserve (~4-5 months runway)
- Current ratio of 1.06x indicates critically tight liquidity with minimal safety margin
- Negative ROE of -1065.7% and ROA of -176.4% reflect operational losses relative to minimal equity base
- Stockholders' equity of only $493.8K makes company highly vulnerable to dilutive financing
- Likely requires significant capital raise or revenue generation within months for survival
- Severe operating losses and deeply negative free cash flow
- Short cash runway and high dilution/going-concern risk
- Execution and regulatory risk with volatile, non-recurring revenue sources
Key Metrics to Watch
- Cash balance trend and runway until additional capital needed
- Path to revenue generation and clinical trial/regulatory milestones
- Operating cash burn rate and burn trend
- Equity dilution from future financing events
- Clinical trial progression and product pipeline advancement
- Quarterly operating cash burn and cash runway
- TTM revenue growth from partnerships/grants/licensing
GeoVax Labs, Inc. (GOVX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
GeoVax Labs, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
GOVX Profit Margin, ROE & Profitability Analysis
GOVX vs Healthcare Sector: How GeoVax Labs, Inc. Compares
How GeoVax Labs, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GeoVax Labs, Inc. Stock Overvalued? GOVX Valuation Analysis 2026
Based on fundamental analysis, GeoVax Labs, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GeoVax Labs, Inc. Balance Sheet: GOVX Debt, Cash & Liquidity
GOVX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: GeoVax Labs, Inc.'s revenue has grown significantly by 117% over the 5-year period, indicating strong business expansion. The most recent EPS of $-120.46 indicates the company is currently unprofitable.
GOVX Revenue Growth, EPS Growth & YoY Performance
GOVX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$5.3M | $-2.62 |
| Q3 2025 | N/A | -$5.1M | $-0.31 |
| Q2 2025 | $300.7K | -$5.1M | $-0.35 |
| Q1 2025 | N/A | -$5.4M | $-0.45 |
| Q3 2024 | N/A | -$4.0M | $-0.91 |
| Q2 2024 | N/A | -$4.0M | $-1.99 |
| Q3 2023 | N/A | -$2.2M | $-0.17 |
| Q2 2023 | N/A | -$2.2M | $-0.18 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
GeoVax Labs, Inc. Dividends, Buybacks & Capital Allocation
GOVX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for GeoVax Labs, Inc. (CIK: 0000832489)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GOVX
What is the AI rating for GOVX?
GeoVax Labs, Inc. (GOVX) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GOVX's key strengths?
Claude: Minimal debt burden with Debt/Equity ratio of 0.00x. $1.3M in cash provides near-term operational runway. ChatGPT: Debt-free balance sheet. Solid current/quick ratio supporting near-term liquidity.
What are the risks of investing in GOVX?
Claude: Zero revenue with no commercial products generating sales. Operating cash burn of $3.5M annually against $1.3M cash reserve (~4-5 months runway). ChatGPT: Severe operating losses and deeply negative free cash flow. Short cash runway and high dilution/going-concern risk.
What is GOVX's revenue and growth?
GeoVax Labs, Inc. reported revenue of $0.0.
Does GOVX pay dividends?
GeoVax Labs, Inc. does not currently pay dividends.
Where can I find GOVX SEC filings?
Official SEC filings for GeoVax Labs, Inc. (CIK: 0000832489) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GOVX's EPS?
GeoVax Labs, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is GOVX's fundamental grade?
Based on our AI fundamental analysis in May 2026, GeoVax Labs, Inc. has a D grade with 90% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is GOVX stock overvalued or undervalued?
Valuation metrics for GOVX: ROE of -1,065.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is GOVX's AI grade for 2026?
Our dual AI analysis gives GeoVax Labs, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GOVX's free cash flow?
GeoVax Labs, Inc.'s operating cash flow is $-3.5M, with capital expenditures of $0.0.
How does GOVX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -1,065.7% (avg: 15%), current ratio 1.06 (avg: 2).